Novavax's COVID-19 booster to be evaluated in NIH study

 Novavax Inc. NVAX, -8.99% said Friday that its experimental COVID-19 booster is being tested in a Phase 1/2 clinical trial sponsored by the National Institutes of Health. This study is evaluating Novavax's protein-based booster candidate in people who have already received the primary series of shots developed by BioNTech SE BNTX, -5.46% and Pfizer Inc. PFE, +0.36%, Johnson & Johnson JNJ, +0.96%, or Moderna Inc. MRNA, -7.66%. (Novavax's COVID-19 vaccine has not been authorized in the U.S.; it is currently being reviewed by the Food and Drug Administration.) The study is enrolling 1,130 adults; approximately 180 of them will receive the Novavax shot as a booster. Novavax's stock has declined 43.0% so far this year, while the S&P 500 SPX, +0.51% is down 5.1%.

https://www.marketwatch.com/story/novavaxs-covid-19-booster-to-be-evaluated-in-nih-study-2022-03-25